loading
Schlusskurs vom Vortag:
$5.36
Offen:
$5.36
24-Stunden-Volumen:
59,589
Relative Volume:
0.13
Marktkapitalisierung:
$322.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.2988
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
-3.46%
1M Leistung:
+16.82%
6M Leistung:
-37.80%
1J Leistung:
-39.89%
1-Tages-Spanne:
Value
$5.26
$5.63
1-Wochen-Bereich:
Value
$5.25
$5.79
52-Wochen-Spanne:
Value
$3.555
$12.92

Astria Therapeutics Inc Stock (ATXS) Company Profile

Name
Firmenname
Astria Therapeutics Inc
Name
Telefon
617-349-1971
Name
Adresse
22 BOSTON WHARF ROAD, BOSTON
Name
Mitarbeiter
78
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-11
Name
Neueste SEC-Einreichungen
Name
ATXS's Discussions on Twitter

Vergleichen Sie ATXS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATXS
Astria Therapeutics Inc
5.56 322.24M 0 -72.89M -68.47M -2.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.44 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.43 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.08 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.75 28.51B 3.81B -644.79M -669.77M -6.24

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-01-31 Eingeleitet JMP Securities Mkt Outperform
2024-07-29 Eingeleitet TD Cowen Buy
2023-03-28 Eingeleitet Evercore ISI Outperform

Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten

pulisher
Jun 18, 2025

(ATXS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan

Jun 18, 2025
pulisher
Jun 15, 2025

HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Astria Therapeutics (ATXS) Receives Reiterated Buy Rating and $1 - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Astria Therapeutics (ATXS) Reports Promising Results for Navenib - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Astria Therapeutics Announces Positive Initial Results from the - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

California State Teachers Retirement System Increases Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Sells 2,042 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Astria Therapeutics Stockholders Approve Key Amendments - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates ATXS FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace

Jun 09, 2025
pulisher
Jun 06, 2025

(ATXS) Investment Report - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 06, 2025

Astria Therapeutics to Present at Upcoming European Academy of A - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | ATXS Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Jane Street Group LLC Has $233,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Acquires Shares of 5,572 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Invests $140,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Jun 03, 2025
pulisher
May 31, 2025

Deutsche Bank AG Buys 13,986 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 31, 2025
pulisher
May 29, 2025

Citizens JMP maintains $25 target on Astria Therapeutics stock By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 28, 2025

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire

May 28, 2025
pulisher
May 26, 2025

Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 26, 2025
pulisher
May 23, 2025

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficien - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop | ATXS Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire

May 23, 2025
pulisher
May 23, 2025

Northern Trust Corp Has $4.10 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 23, 2025
pulisher
May 22, 2025

Astria Therapeutics to Present at Upcoming Eastern Allergy Confe - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference | ATXS Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

New Clinical Data: Astria's Navenibart Cuts Hereditary Angioedema Attack Severity, Reduces Rescue Med Usage - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - New Castle News

May 22, 2025
pulisher
May 21, 2025

Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00 - Defense World

May 21, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 18, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Analysts Lower Earnings Estimates for ATXS - Defense World

May 18, 2025
pulisher
May 17, 2025

Wedbush Lowers Earnings Estimates for Astria Therapeutics - Defense World

May 17, 2025
pulisher
May 17, 2025

Q2 EPS Estimate for Astria Therapeutics Lowered by Analyst - Defense World

May 17, 2025
pulisher
May 17, 2025

Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

May 17, 2025
pulisher
May 16, 2025

FMR LLC Reduces Holdings in Astria Therapeutics Inc - GuruFocus

May 16, 2025
pulisher
May 16, 2025

(ATXS) Technical Data - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

Astria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 15, 2025

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail

May 15, 2025
pulisher
May 15, 2025

Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs - TipRanks

May 15, 2025
pulisher
May 14, 2025

Analyst Reiterates Overweight Rating for ATXS with Stable Price Target | ATXS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - Yahoo Finance

May 14, 2025

Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.95
price up icon 1.40%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):